JP Morgan Chase
SGMO

JP Morgan Chase’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

JP Morgan Chase’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$150 Hold
489
– – ﹤0.01% 7278
2025
Q4 		$205 Buy
+489
New +$259 ﹤0.01% 7155
2025
Q1 		– Sell
-25,000
Closed -$25.5K – 7684
2024
Q4 		$25.5K Buy
25,000
+21,793
+680% +$39.8K ﹤0.01% 6201
2024
Q3 		$2.78K Hold
3,207
– – ﹤0.01% 6579
2024
Q2 		$1.15K Sell
3,207
-1,319,341
-100% -$713K ﹤0.01% 6598
2024
Q1 		$886K Sell
1,322,548
-50,727
-4% -$36.8K ﹤0.01% 4435
2023
Q4 		$746K Sell
1,373,275
-32,871
-2% -$15.2K ﹤0.01% 4531
2023
Q3 		$843K Sell
1,406,146
-76,270
-5% -$81.7K ﹤0.01% 4170
2023
Q2 		$1.93M Sell
1,482,416
-91,756
-6% -$125K ﹤0.01% 3573
2023
Q1 		$2.77M Buy
1,574,172
+11,863
+0.8% +$33.9K ﹤0.01% 3296
2022
Q4 		$4.91M Buy
1,562,309
+18,796
+1% +$72.9K ﹤0.01% 2830
2022
Q3 		$7.56M Buy
1,543,513
+32,815
+2% +$169K ﹤0.01% 2386
2022
Q2 		$6.25M Buy
1,510,698
+8,890
+0.6% +$38.4K ﹤0.01% 2580
2022
Q1 		$8.73M Sell
1,501,808
-82,181
-5% -$489K ﹤0.01% 2507
2021
Q4 		$11.9M Sell
1,583,989
-433,487
-21% -$3.77M ﹤0.01% 2298
2021
Q3 		$18.2M Sell
2,017,476
-1,259,311
-38% -$12.4M ﹤0.01% 1849
2021
Q2 		$39.2M Buy
3,276,787
+422,964
+15% +$4.79M ﹤0.01% 1345
2021
Q1 		$35.8M Buy
2,853,823
+1,071,188
+60% +$14.4M ﹤0.01% 1331
2020
Q4 		$27.8M Buy
1,782,635
+802,865
+82% +$9.41M ﹤0.01% 1392
2020
Q3 		$9.69M Buy
979,770
+207,140
+27% +$2.24M ﹤0.01% 2063
2020
Q2 		$6.92M Buy
772,630
+149,736
+24% +$1.39M ﹤0.01% 2200
2020
Q1 		$3.97M Buy
622,894
+321,261
+107% +$2.38M ﹤0.01% 2460
2019
Q4 		$2.52M Buy
301,633
+193,444
+179% +$1.78M ﹤0.01% 3211
2019
Q3 		$980K Buy
108,189
+8,166
+8% +$91.6K ﹤0.01% 3852
2019
Q2 		$1.05M Buy
100,023
+2,372
+2% +$25.2K ﹤0.01% 3840
2019
Q1 		$931K Sell
97,651
-5,785
-6% -$59.1K ﹤0.01% 3847
2018
Q4 		$1.19M Sell
103,436
-2,275
-2% -$28.3K ﹤0.01% 3635
2018
Q3 		$1.79M Buy
105,711
+7,817
+8% +$119K ﹤0.01% 3534
2018
Q2 		$1.39M Sell
97,894
-994
-1% -$16.5K ﹤0.01% 3649
2018
Q1 		$1.88M Buy
98,888
+77,937
+372% +$1.67M ﹤0.01% 3301
2017
Q4 		$344K Buy
20,951
+18,736
+846% +$279K ﹤0.01% 4233
2017
Q3 		$32K Buy
2,215
+225
+11% +$2.49K ﹤0.01% 4557
2017
Q2 		$18K Sell
1,990
-9,756
-83% -$62.6K ﹤0.01% 4555
2017
Q1 		$61K Buy
11,746
+10,426
+790% +$41.8K ﹤0.01% 4476
2016
Q4 		$4K Buy
+1,320
New +$4.81K ﹤0.01% 4883
2016
Q3 		– Sell
-771
Closed -$4K – 4772
2016
Q2 		$4K Sell
771
-83
-10% -$529 ﹤0.01% 4495
2016
Q1 		$6K Buy
854
+771
+929% +$4.63K ﹤0.01% 4342
2015
Q4 		$1K Buy
+83
New +$640 ﹤0.01% 4614
2015
Q2 		– Sell
-120,877
Closed -$1.9M – 4155
2015
Q1 		$1.9M Buy
120,877
+12,014
+11% +$186K ﹤0.01% 2904
2014
Q4 		$1.66M Buy
+108,863
New +$1.32M ﹤0.01% 3069
2013
Q4 		– Sell
-41,514
Closed -$435K – 4216
2013
Q3 		$435K Sell
41,514
-17,928
-30% -$178K ﹤0.01% 3700
2013
Q2 		$464K Buy
+59,442
New +$519K ﹤0.01% 3645

Other funds holding SGMO

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's SGMO Position: Q1 2026 in Review

JP Morgan Chase held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 489 shares worth $150. The position accounts for ﹤0.01% of the portfolio, ranked #7278.

JP Morgan Chase first reported a position in SGMO in Q2 2013 and has held it in 42 quarters since. The position peaked at $39.2M in Q2 2021. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.

  • JP Morgan Chase held 489 shares of SANGAMO THERAPEUTICS INC worth $150 as of Q1 2026.
  • JP Morgan Chase left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7278 holding.
  • JP Morgan Chase first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 42 quarters since.
  • JP Morgan Chase's SANGAMO THERAPEUTICS INC position peaked at $39.2M in Q2 2021.
  • 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.